Home › Calculator › DTIL Dividend Calculator 2026
DTIL Dividend DRIP Calculator 2026
26.77% YieldHealthcarePrecision BioSciences, Inc. · NASDAQ
Price: $7.47 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When DTIL pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your DTIL snowball 📈
$10,000 in DTIL → $8335934.10M in 10 years · $692,136,633,386.29/month
About Precision BioSciences, Inc. (DTIL) — Dividend Analysis 2026
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Compare DTIL with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full DTIL DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open DTIL position with:
🌍 DTIL Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold DTIL.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 26.77% | 23.97% | $2,677 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 22.75% | 19.95% | $2,275 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 21.42% | 18.62% | $2,142 / yr |
| 🇬🇧 UK ISA | 0% | 26.77% | 23.97% | $2,677 / yr |
| 🇬🇧 UK Taxable | 8.75% | 24.43% | 21.63% | $2,443 / yr |
| 🇨🇦 TFSA | 0% | 26.77% | 23.97% | $2,677 / yr |
| 🇨🇦 CA Taxable | 25% | 20.08% | 17.28% | $2,008 / yr |
| 🇦🇺 Super (pension) | 15% | 22.75% | 19.95% | $2,275 / yr |
| 🇦🇺 AU Taxable | 30% | 18.74% | 15.94% | $1,874 / yr |
| 🇩🇪 DE Taxable | 26.375% | 19.71% | 16.91% | $1,971 / yr |
| 🇫🇷 FR Taxable | 30% | 18.74% | 15.94% | $1,874 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 DTIL Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 DTIL Dividend Payment Schedule
DTIL pays quarterly — 4 times per year. Next ex-div: TBD.
📊 DTIL vs Healthcare Benchmarks
How DTIL compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for DTIL sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ DTIL Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Other | 2026-08-01 | 235 | $36.00 | $8.5K | ||
| Other | 2026-08-01 | 585 | $359.40 | $210.2K | ||
| Other | 2026-08-01 | 179,340 | — | — | ||
| Other | 2026-08-01 | 945 | $378.00 | $357.2K | ||
| Other | 2026-08-01 | 214 | $174.90 | $37.4K | ||
| Other | 2026-08-01 | 403 | $340.20 | $137.1K | ||
| Other | 2026-08-01 | 778 | $122.40 | $95.2K | ||
| Other | 2026-08-01 | 30,129 | — | — | ||
| Other | 2026-08-01 | 179,340 | — | — | ||
| A-Award | 2026-06-03 | 20,979 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the DTIL dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Precision BioSciences, Inc. (DTIL) is currently trading at $7.47, 98% below its 52-week high. The current dividend yield is 26.77% based on an annual payout of $2.00 per share.
DTIL (Precision BioSciences, Inc.) — 26.77% Dividend Yield Analysis
Precision BioSciences, Inc. (DTIL) is a healthcare stock currently trading at $7.47 with a dividend yield of 26.77%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (26.77%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.